InvestorsHub Logo
Followers 2
Posts 188
Boards Moderated 0
Alias Born 01/09/2019

Re: dcaf7 post# 307

Friday, 03/24/2023 12:42:45 PM

Friday, March 24, 2023 12:42:45 PM

Post# of 572
Getting a first look at the population that responds to Tus/Ven double will be highly informative, especially versus Tus alone. Furthermore the big question right now is how myleo-suppressive is the combination. The design of a registrational double trial will become clear AFTER they meet with the FDA. They need this initial data for that meeting.

I think a ven only arm in this patient population will be judged unethical. It won't happen.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APTO News